Aratana Therapeutics, Inc. to Post Q1 2018 Earnings of ($0.20) Per Share, William Blair Forecasts (PETX)
Aratana Therapeutics, Inc. (NASDAQ:PETX) – Stock analysts at William Blair issued their Q1 2018 earnings per share (EPS) estimates for shares of Aratana Therapeutics in a report issued on Sunday. William Blair analyst J. Kreger forecasts that the biopharmaceutical company will earn ($0.20) per share for the quarter. William Blair also issued estimates for Aratana Therapeutics’ Q3 2018 earnings at ($0.03) EPS.
Aratana Therapeutics (NASDAQ:PETX) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.03. The business had revenue of $5.16 million during the quarter, compared to analysts’ expectations of $4.50 million. Aratana Therapeutics had a negative net margin of 642.93% and a negative return on equity of 51.21%. The company’s quarterly revenue was down 86.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.61 earnings per share. TRADEMARK VIOLATION WARNING: This report was reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/aratana-therapeutics-inc-to-post-q1-2018-earnings-of-0-20-per-share-william-blair-forecasts-petx/1636543.html.
Other equities analysts also recently issued research reports about the stock. BidaskClub downgraded shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. ValuEngine upgraded shares of Aratana Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 25th. Lake Street Capital cut their price target on shares of Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating for the company in a report on Friday, August 25th. Zacks Investment Research downgraded shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 13th. Finally, Jefferies Group LLC set a $8.00 price target on shares of Aratana Therapeutics and gave the company a “buy” rating in a report on Friday, August 4th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. Aratana Therapeutics presently has an average rating of “Hold” and an average target price of $8.25.
Aratana Therapeutics (PETX) remained flat at $6.55 during mid-day trading on Tuesday. The stock had a trading volume of 64,474 shares. The stock has a 50 day moving average of $6.06 and a 200-day moving average of $6.23. The stock’s market capitalization is $281.66 million. Aratana Therapeutics has a 52 week low of $4.97 and a 52 week high of $9.23.
In other news, insider Peter Steven St sold 50,000 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $6.24, for a total value of $312,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ernst Heinen sold 10,000 shares of the stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $6.25, for a total transaction of $62,500.00. Following the completion of the transaction, the insider now owns 130,994 shares of the company’s stock, valued at approximately $818,712.50. The disclosure for this sale can be found here. Insiders sold a total of 70,000 shares of company stock valued at $435,600 in the last quarter. Insiders own 5.20% of the company’s stock.
Large investors have recently bought and sold shares of the business. Wells Fargo & Company MN increased its holdings in Aratana Therapeutics by 281.4% during the 1st quarter. Wells Fargo & Company MN now owns 276,152 shares of the biopharmaceutical company’s stock valued at $1,464,000 after acquiring an additional 203,738 shares in the last quarter. Janney Montgomery Scott LLC increased its holdings in Aratana Therapeutics by 7.9% during the 2nd quarter. Janney Montgomery Scott LLC now owns 16,400 shares of the biopharmaceutical company’s stock valued at $119,000 after acquiring an additional 1,200 shares in the last quarter. Williams Jones & Associates LLC purchased a new position in Aratana Therapeutics during the 2nd quarter valued at about $827,000. Geneva Advisors LLC increased its holdings in Aratana Therapeutics by 3.7% during the 2nd quarter. Geneva Advisors LLC now owns 80,118 shares of the biopharmaceutical company’s stock valued at $579,000 after acquiring an additional 2,830 shares in the last quarter. Finally, Weiss Multi Strategy Advisers LLC increased its holdings in Aratana Therapeutics by 8.3% during the 1st quarter. Weiss Multi Strategy Advisers LLC now owns 65,000 shares of the biopharmaceutical company’s stock valued at $345,000 after acquiring an additional 5,000 shares in the last quarter. Hedge funds and other institutional investors own 73.08% of the company’s stock.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.